Program
divarasib
Also written as “Divarasib” and “GDC-6036”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by Hoffmann-La Roche.
Furthest: phase 3, since Jun 5, 201713 company-led studies, 9 open or runningNext primary completion: Nov 30, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 139 open or running | phase 3since Jun 5, 2017 | Jun 5, 2017 | Nov 30, 2026phase 2 · NCT04302025 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6330 divarasib
, phase 3, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 5, 2017First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03178552 · 1,000 enrolled · United States, Argentina, Australia and more
- Mar 6, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04302025 · 99 enrolled · United States
- Jun 24, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04449874 · 498 enrolled · United States, Australia, Belgium and more
- Oct 11, 2020Phase 2 study in Solid TumorsNCT04589845 · 920 enrolled · United States, Australia, Belgium and more
- Jun 11, 2021Phase 1 study in Colorectal NeoplasmsNCT04929223 · 542 planned · United States, Australia, Canada and more
- Feb 21, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05789082 · 320 planned · United States, Argentina, Australia and more
- Jul 5, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06497556 · 338 enrolled · United States, Argentina, Australia and more
- Nov 5, 20242 phase 1 studies in Healthy ParticipantsNCT06677957, NCT06690138
- Dec 11, 2024Phase 1 study in Hepatic ImpairmentNCT06734208 · 31 enrolled · United States
- Jan 20, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06793215 · 600 planned · United States, Argentina, Australia and more
- Feb 14, 2025Phase 1 study in Healthy ParticipantsNCT06835465 · 18 enrolled · United States
- Apr 14, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07541170 · 400 planned · United States, Argentina, Belgium and more
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04302025
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT03178552
- Dec 31, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT04449874
- Nov 30, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06793215
TargetBeta
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, divarasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, s…”NCIt, read by Claude
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07541170Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Recruiting | Jan 31, 2032 | 400 |
| NCT06835465Healthy Participants · United States | 1 | Completed | May 6, 2025 | 18 |
| NCT06793215Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Nov 30, 2028 | 600 |
| NCT06734208Hepatic Impairment · United States | 1 | Completed | Nov 27, 2025 | 31 |
| NCT06690138Healthy Participants · United States | 1 | Completed | Feb 11, 2025 | 18 |
| NCT06677957Healthy Participants · United States | 1 | Completed | Dec 30, 2024 | 19 |
| NCT06497556Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 19, 2026 | 338 |
| NCT05789082Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Recruiting | Jan 29, 2032 | 320 |
| NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Aug 31, 2030 | 542 |
| NCT04589845Solid Tumors · United States, Australia, Belgium and more | 2 | Active, not recruiting | Sep 25, 2032 | 920 |
| NCT04449874Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 1 | Active, not recruiting | Dec 31, 2027 | 498 |
| NCT04302025Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Nov 30, 2026 | 99 |
| NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 30, 2027 | 1,000 |
How it is read
Names in the registry
- “Divarasib”, 12 entries
- “GDC-6036”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.